Thin
Direct factory catalog offering synthetic purity exceeding 99.0%, verified via HPLC-MS, with comprehensive regulatory support files and worldwide cold-chain transport.
Body Protection Compound 157 (BP 157, CAS No. 137525-51-0) is a 15-amino acid peptide derived from human gastric juice protein BPC. Understanding its stereochemical integrity and synthetic pathways is crucial for pharmaceutical-grade procurement.
Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The molecular formula is C62H98N16O22. Because of three consecutive proline residues, steric hindrance requires specialized microwave-assisted coupling protocols during Fmoc-SPPS to prevent truncated sequences such as des-Pro deletion analogs.
Crude synthesis yields Trifluoroacetic acid (TFA) salts, which can induce cytotoxicity in cellular and clinical research. Our production line applies industrial ion-exchange chromatography to convert TFA salts into biocompatible Acetate or sterile Hydrochloride forms, maintaining residual TFA below 0.1%.
Formulated as a sterile lyophilized cake using pharmacopeial bulking matrices (such as low-moisture D-mannitol or glycine). Controlled freezing cycles (-45°C primary freeze with sublimation under < 0.05 mbar vacuum) ensure an amorphous cake with immediate reconstitution kinetics in bacteriostatic water.
An objective assessment of global supply shifts, shifting regulatory expectations across Western territories, and the industrial transition from compounding pharmacy supply to cGMP multi-kilogram manufacturing.
Body Protection Compound 157 has achieved widespread scientific prominence over the past decade. Known chemically as the pentadecapeptide BPC-157, it has demonstrated robust tissue healing, angiogenic modulation through the upregulation of vascular endothelial growth factor (VEGF), and accelerated tendon-to-bone integration in preclinical literature. As a result, commercial research demand across biotechnology incubators, clinical testing groups, sports science laboratories, and compounding pharmacies has accelerated dramatically.
Historically, the market was bifurcated between small-scale academic research batches and unstandardized chemical distributors. Today, international pharmaceutical buyers require rigorous supply chain transparency, validated sterility assurance levels (SAL 10^-6), and fully traceable chemistry, manufacturing, and control (CMC) packages.
Regulatory categorization updates by the FDA concerning 503A and 503B compounding pharmacies have shifted procurement requirements. Sourcing managers now bypass domestic brokers to partner directly with primary peptide API manufacturers capable of providing multi-kilogram Master Drug Files, robust impurity profiling, and cold-chain compliance.
In the EU, regulatory agencies demand comprehensive mass spectrometry sequencing, D-amino acid stereoisomeric checks, and residual solvent quantification below ICH Q3C limits. Procurement teams focus heavily on the elimination of elemental heavy metal catalysts used during coupling and cleavage steps.
Biopharma centers in the Middle East, CIS, and Latin America are expanding regenerative medicine trials and veterinary orthopedic research programs, requiring turnkey OEM private-label finished injectable vial services ranging from 2mg to 10mg per vial with custom batch labeling and sterilization data.
These structural shifts have positioned large-scale Chinese synthesis centers as indispensable strategic partners. By integrating amino acid raw-material manufacturing, automated solid-phase synthesizer parks, and industrial-scale lyophilization halls, China-based facilities provide the global supply security that fragmented compounding laboratories cannot match.
How geographical manufacturing integration, raw material localization in Hangzhou, and multi-ton scale lower wholesale API unit costs by up to 55% while maintaining strict analytical precision.
China produces over 70% of the world's Fmoc-protected amino acids, coupling reagents (such as HATU, HBTU, and DIC), and CTC resin matrices. Localized procurement eliminates customs overhead and lead times for critical synthesis reagents.
Operating automated solid-phase synthesizers ranging from 50L pilot reactors to 1,000L commercial glass-lined reactors. Batch-to-batch reproducibility is managed via computer-controlled automated reagent injection and monitoring systems.
Purification utilizes Dynamic Axial Compression (DAC) HPLC columns up to 600mm diameter. This infrastructure enables single-run purifications of multi-kilogram peptide crude, achieving ≥99.0% chromatographic purity in a fraction of the time.
All finished lyophilized injection vials undergo helium leak detection and automated optical inspection before transfer into temperature-controlled international cold-chain packaging (-20°C with digital data logger tracking).
Indicative wholesale B2B tiered quotes for enterprise pharmaceutical buyers, biotech labs, and licensed distributors. Final project costs reflect counter-ion choice, vial fill volume, and regulatory packaging specifications.
| Product Grade & Specification | Format / Fill | Purity (RP-HPLC) | MOQ Tier | Indicative Price (USD) | Batch Lead Time | Testing Documentation |
|---|---|---|---|---|---|---|
| BP 157 Standard Research Grade | 5mg / Vial (Lyophilized) | ≥ 98.5% | 100 Vials | $4.20 - $5.50 / vial | In Stock / 3 Days | CoA, HPLC, MS |
| BP 157 Ultra-Pure Clinical Tier | 5mg / Vial (Lyophilized) | ≥ 99.2% | 500 Vials | $3.40 - $4.10 / vial | 5 - 7 Business Days | HPLC, MS, Endotoxin |
| BP 157 High-Dose Formulation | 10mg / Vial (Lyophilized) | ≥ 99.0% | 200 Vials | $6.80 - $8.20 / vial | In Stock / 4 Days | Complete CoA |
| BP 157 Bulk Commercial API Powder | Custom Sealed Foil Bag | ≥ 99.0% (Acetate Salt) | 100 Grams | $45.00 - $60.00 / g | 7 - 10 Days | Full CMC Dossier |
| BP 157 Enterprise CDMO Campaign | 1kg+ Bulk API / Custom Vials | ≥ 99.5% (Low Endotoxin) | 1.0 Kilogram | Inquire for Contract Rates | Scheduled Campaign | Audit Ready / DMF |
* Note: Prices listed above are FOB Hangzhou or CIF Major Airport. For custom lyophilization matrix formulations (e.g., specific Mannitol-to-Peptide ratios, nitrogen flushing, or colored flip-off tear caps), please submit a customized Request for Proposal (RFP). Custom formulation services operate under cGMP cleanroom conditions (ISO Class 5 environment).
Every commercial lot must satisfy a six-tier analytical matrix before release. Sourcing directors rely on these empirical standards to guarantee compliance with international pharmacopeial limits.
Testing on Agilent 1260/1290 Infinity II systems utilizing C18 columns (4.6 × 250 mm, 5 μm) with water/acetonitrile gradients containing 0.1% TFA. Total purity is quantified by peak area integration. Individual unknown impurities must not exceed 0.5%, with total related substances under 1.0%.
High-resolution Electrospray Ionization Mass Spectrometry confirms the monoisotopic mass of the pentadecapeptide at [M+H]+ = 1420.53 ± 1.0 Da and [M+2H]2+/2 multicharged states, verifying that no amino acid misincorporations or racemizations have occurred during chain assembly.
For parenteral and injectable research grades, bacterial endotoxins are quantified using kinetic turbidimetric Limulus Amebocyte Lysate (LAL) assays per USP <85>, verifying endotoxin concentrations < 0.5 EU/mg. Bioburden testing conforms strictly with USP <71> membrane filtration.
Quantification of volatile organic impurities (acetonitrile, dichloromethane, diisopropylethylamine, N,N-dimethylformamide) via Headspace Gas Chromatography with flame ionization detection (GC-FID) ensures strict compliance with ICH Q3C Class 2 and Class 3 guidelines.
Lyophilized vials undergo real-time stability testing at 2°C - 8°C as well as accelerated testing at 25°C / 60% Relative Humidity per ICH Q1A(R2). Stability reports indicate less than 0.8% degradation over 24 months when stored dry at recommended frozen temperatures (-20°C).
Particulate matter in reconstituted parenteral solutions is analyzed via light obscuration particulate count test according to USP <788>. Verifications confirm particulate levels remain well below the pharmacopeial limits for particles ≥10 μm and ≥25 μm per container.
Detailed technical answers addressing batch sizing, custom synthesis turnaround times, TFA salt removal, and international customs clearance protocols.
Crude BP 157 post-cleavage typically exhibits purities between 65% and 75% due to truncated peptide fragments and protecting group adducts. Our multi-stage preparative DAC HPLC purification refines this crude material to ≥99.0% purity, effectively eliminating D-amino acid stereoisomers and deletion sequences.
Trifluoroacetic acid (TFA) is a standard cleavage agent in solid-phase synthesis. However, residual TFA counter-ions can cause localized cellular toxicity and physiological irritation in sensitive vivo biological models. Converting the peptide to an acetate or hydrochloride salt form ensures biocompatibility and physiologic tolerance.
Our standard formulation utilizes pharmacopeial grade D-mannitol (typically 20mg to 50mg per vial depending on active fill) to form a robust, crack-free lyophilized cake. Custom projects can request trehalose, sucrose, or glycine bulking agents tailored for specific stability and reconstitution speed profiles.
Standard 5mg and 10mg catalog vials are kept in controlled cold-chain stock and ship within 48 to 72 hours via express door-to-door temperature-monitored courier. Custom batch synthesis (100g to 2kg API powder or custom-labeled vials) requires approximately 2 to 3 weeks for synthesis, purification, QC release, and lyophilization.
We provide comprehensive regulatory export documentation including non-toxic synthetic compound declarations, accurate HS code categorization (2937.19), Certificates of Origin, Certificate of Analysis (CoA), and Material Safety Data Sheets (MSDS) to facilitate expedited import clearance across North America, Europe, Asia, and Latin America.
Each batch is released with a lot-specific Certificate of Analysis featuring high-resolution RP-HPLC chromatograms with integration tables, ESI-MS molecular identity spectra, Karl Fischer water determination, residual acetate/TFA content quantification, and endotoxin assay reports.
Browse our extended portfolio of multi-ton peptide APIs, ranging from dual and tri-receptor incretin mimetics to advanced dermatological signaling peptides and peptide agonists.
